Cure8 trial brief
Phase 1 platform studies like this one test safety and tolerability of new treatments for moderate-to-severe ulcerative colitis before larger trials. Findings from such early studies determine whether a drug moves forward and what risks need closer monitoring.
Adults with moderate-to-severe ulcerative colitis, clinicians who care for UC patients, and researchers interested in early-stage drug development or platform trial designs.
This is a clinicaltrials.gov registration for a Phase 1, not-yet-recruiting platform study testing multiple interventions in adults with moderate-to-severe ulcerative colitis.
The record lists a sub-study intervention named Aletekitug (GSK1070806) and focuses on safety and tolerability with planned collection of adverse events, labs, and vital signs over ~34 weeks.
Eligibility, key exclusion criteria (including prior colectomy, active infections, prior biologics/small molecules) and endoscopic disease requirements are described in the record. The entry is a trial record (Phase 1) and reports planned design and outcomes (safety/tolerability measures) rather than results.
It appears to be an early-stage safety platform where different sub-studies can be added under a master protocol. The trial is not yet recruiting and planned enrollment is small (16) as listed in the registry.
If you are considering participation, the registry shows detailed inclusion/exclusion rules (endoscopic confirmation, disease extent, medication washouts) and common safety monitoring that would apply. Discuss any interest with your treating clinician or study site for specifics about risks, logistics, and whether prior therapies make you ineligible.
This is a registry record describing a planned Phase 1 study (not yet recruiting) and does not report results. The listed intervention (Aletekitug / GSK1070806) and safety endpoints are from the sponsor's submission; enrollment is small and the primary focus is safety, not efficacy.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Early-phase trials test safety and tolerability of new mechanisms; this study evaluates an anti–IL-18 antibody (aletekitug) which could represent a different therapeutic approach for people with moderate-to-severe UC if...
This NIH natural-history study is collecting clinical, immune, and genetic samples from people with Crohn’s disease and ulcerative colitis to better understand immune pathways and molecular causes of IBD. Those findings...
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
